pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

NCT05402059 ·Status: UNKNOWN

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

NCT04666272 ·Status: ACTIVE_NOT_RECRUITING

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

NCT01767454 ·Status: COMPLETED ·Phase: PHASE1

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

NCT03944356 ·Status: COMPLETED

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236 ·Status: TERMINATED ·Phase: PHASE2

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

NCT05260684 ·Status: COMPLETED

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

NCT02416232 ·Status: NO_LONGER_AVAILABLE

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

NCT02143050 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Radiotherapy & Combi in Metastatic Melanoma

NCT02392871 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

NCT04544202 ·Status: NO_LONGER_AVAILABLE

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

NCT03551626 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

NCT01972347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

NCT02143999 ·Status: COMPLETED

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

NCT03514901 ·Status: UNKNOWN ·Phase: PHASE2

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

NCT02410863 ·Status: TERMINATED ·Phase: PHASE2

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

NCT04759846 ·Status: WITHDRAWN ·Phase: PHASE1

Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma

NCT06774989 ·Status: RECRUITING

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

NCT02083354 ·Status: COMPLETED ·Phase: PHASE2

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

NCT06251934 ·Status: COMPLETED

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355 ·Status: COMPLETED ·Phase: PHASE1

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

NCT04547946 ·Status: COMPLETED

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

NCT07092410 ·Status: WITHDRAWN ·Phase: PHASE4

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

NCT04489433 ·Status: NO_LONGER_AVAILABLE